Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vertex Pharmaceuticals (NQ: VRTX ) 495.26 +3.00 (+0.61%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Vertex Pharmaceuticals < Previous 1 2 3 4 5 6 Next > Vertex to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 15th September 13, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Announces Publication in The New England Journal of Medicine of Phase 3 Results for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People With Cystic Fibrosis August 26, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer August 04, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Reports Second-Quarter 2021 Financial Results July 29, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis July 28, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain July 19, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex to Announce Second-Quarter 2021 Financial Results on July 29 July 16, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Announces National Reimbursement Agreement in France for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) and SYMKEVI® (tezacaftor/ivacaftor) for Eligible Cystic Fibrosis Patients June 28, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Announces New Portfolio Reimbursement Agreement in Italy Including KAFTRIO®, SYMKEVI® and Additional Indications of ORKAMBI® and KALYDECO® for Eligible Patients With Cystic Fibrosis June 25, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older Who Have at Least One F508del Mutation June 18, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting June 11, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency June 10, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire CORRECTING and REPLACING Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations June 09, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations June 09, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex to Present at the Bank of America Securities 2021 Virtual Health Care Conference on May 13 May 10, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Reports First-Quarter 2021 Financial Results April 29, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing April 22, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex to Announce First-Quarter 2021 Financial Results on April 29 April 19, 2021 From Vertex Pharmaceuticals Incorporated Via Business Wire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.